NCCN Clinical Practice Guidelines in Oncology: Prostate cancer, 2013. www.nccn.org

Horwich, A., Hugosson, J., de Reijke, T., et al.: Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann. Oncol., 2013, 24(5), 1141–1162.

Ottó, S., Kásler, M.: Trends in cancer mortality and morbidity in Hungarian and international statistics. Characteristics and potential outcome of public health screening programs. [A hazai és nemzetközi daganatos halálozási és megbetegedési mutatók alakulása. A népegészségügyi programok jellegzetességei és várható eredményei.] Magy. Onkol., 2005, 49(2), 99–107. [Hungarian]

Vrdoljak, E., Wojtukiewicz, M. Z., Pienkowski, T., et al.: Cancer epidemiology in Central and South Eastern European countries. Croat. Med. J., 2011, 52(4), 478–487.

Bray, F., Lortet-Tieulent, J., Ferlay, J., et al.: Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur. J. Cancer, 2010, 46(17), 3040–3052.

Peeters, S. T., Heemsbergen, W. D., Koper, P. C., et al.: Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J. Clin. Oncol., 2006, 24(13), 1990–1996.

Zietman, A. L., DeSilvio, M. L., Slater, J. D., et al.: Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA, 2005, 294(10), 1233–1239.

Kuban, D. A., Tucker, S. L., Dong, L., et al.: Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 2008, 70(1), 67–74.

Viani, G. A., da Silva, L. G., Stefano, E. J.: High-dose conformal radiotherapy reduces prostate cancer-specific mortality: results of a meta-analysis. Int. J. Radiat. Oncol. Biol. Phys., 2012, 83(5), e619–e625.

Créhange, G., Martin, E., Supiot, S., et al.: Image-guided radiotherapy in prostate cancer: concepts and implications. Cancer Radiother., 2012, 16(5–6), 430–438.

Soete, G., Verellen, D., Storme, G.: Image guided radiotherapy for prostate cancer. Bull. Cancer, 2008, 95(3), 374–380.

Bauman, G., Rumble, R. B., Chen, J., et al.: Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin. Oncol. (R. Coll. Radiol.), 2012, 24(7), 461–473.

Boehmer, D., Maingon, P., Poortmans, P., et al.: Guidelines for primary radiotherapy of patients with prostate cancer. Radiother. Oncol., 2006, 79(3), 259–269.

Balogh, F.: Urological diseases in old age. Magy. Seb., 1963, 16, 121–124. [Hungarian]

Noszkay, A.: Developments in the therapy of 2 typical diseases of aging males. Orv. Hetil., 1973, 114(17), 971–976.

Frang, D., Hübler, J.: Complex treatment and care of prostatic carcinoma patients. Acta Chir. Hung., 1987, 28(3), 167–175.

Sápi, Z., Bodó, M., Vadász, G., et al.: The increasing incidence of prostate cancer in Hungary. In Vivo, 1994, 8(3), 433–435.

Romics, I.: Treatment of prostate cancer. [A prostatarák kezelése.] Orv. Hetil., 2010, 151(14), 580–583. [Hungarian]

Ágoston, P., Major, T., Somogyi, A., et al.: Brachytherapy boost irradiation in the treatment of high risk, localised prostate cancer. Initial national experience in Hungary. [Brachyterápiás boost besugárzás nagy kockázatú, lokalizált prosztatarák kezelésében: első hazai tapasztalatok.] Magy. Onkol., 2004, 48(1), 81–88. [Hungarian]

Ágoston, P., Major, T., Fröhlich, G., et al.: Moderate dose escalation with single-fraction high-dose-rate brachytherapy boost for clinically localized intermediate- and high-risk prostate cancer: 5-year outcome of the first 100 consecutively treated patients. Brachytherapy, 2011, 10(5), 376–384.

Fröhlich, G., Ágoston, P., Lövey, J., et al.: Dosimetric evaluation of high-dose-rate interstitial brachytherapy boost treatments for localized prostate cancer. Strahlenther. Onkol., 2010, 186(7), 388–395.

Ágoston, P., Major, T., Fröhlich, G., et al.: Permanent implant brachytherapy for early, organ-confined prostate cancer. [Permanens implantációs prosztata-brachyterápia korai, szervre lokalizált prosztatarák kezelésére.] Magy. Onkol., 2011, 55(3), 170–177. [Hungarian]

Lakosi, F., Antal, G., Vandulek, C., et al.: Open MR-guided high-dose-rate (HDR) prostate brachytherapy: feasibility and initial experiences open MR-guided high-dose-rate (HDR) prostate brachytherapy. Pathol. Oncol. Res., 2011, 17(2), 315–324.

Czigner, K., Ágoston, P., Forgács, G., et al.: The effect of different patient positions on overlapping volumes in radiotherapy of high-risk prostate cancer patients. [A betegfektetés hatása a védendő szervek és a céltérfogatok átfedésére nagy kockázatú prosztatarákos betegek sugárkezelésekor.] Magy. Onkol., 2011, 55(4), 281–285. [Hungarian]

Szabó, Z., Ágoston, P., Major, T., et al.: Comparison of CT- and MRI-based clinical target volumes for 3 dimensional conformal external-beam radiotherapy of prostate cancer. [CT és MRI alapján meghatározott céltérfogatok összehasonlítása prosztatarákos betegek 3 dimenziós konformális külső sugárkezelésében.] Magy. Onkol., 2012, 56(4), 267–273. [Hungarian]

Kliton, J., Ágoston, P., Major, T., et al.: Evaluation of patient positioning using in-room kV CT for image-guided radiotherapy (IGRT) of prostate cancer. [Kilovoltos CT-vel végzett betegbeállítás vizsgálata prosztatarákos betegek képvezérelt külső besugárzásakor.] Magy. Onkol., 2012, 56(3), 193–198. [Hungarian]

Major, T., Ágoston, P., Jorgo, K., et al.: Application of image-guided radiotherapy in external beam radiation of cancer patients. [Képvezérelt sugárterápia klinikai alkalmazása daganatos betegek külső besugárzásánál.] Magy. Onkol., 2012, 56(4), 258–265. [Hungarian]

Mangel, L., Kövér, E., Szilágyi, I., et al.: Novel quality assurance method in oncology: the two-level, multi-disciplinary and oncotherapy oncology team system. [Új típusú minőségbiztosítás az onkológiában: a kétlépcsős (multidiszciplináris és onkoterápiás) onkoteamrendszer.] Orv. Hetil., 2012, 153(50), 1984–1991. [Hungarian]

Poortmans, P., Bossi, A., Vandeputte, K., et al.: Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother. Oncol., 2007, 84(2), 121–127.

Boehmer, D., Maingon, P., Poortmans, P., et al.: Guidelines for primary radiotherapy of patients with prostate cancer. Radiother. Oncol., 2006, 79(3), 259–269.

Lawton, C. A., Michalski, J., El-Naqa, I., et al.: RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 2009, 74(2), 383–387.

Macías, V., Biete, A.: Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials. Clin. Transl. Oncol., 2009, 11(7), 437–445.

Lennernäs, B., Nilsson, S., Levitt, S., et al.: Hypofractionation for radiotherapy of prostate cancer using a low alfa/beta ratio – possible reasons for concerns? An example of five dimensional radiotherapy. Acta Oncol., 2011, 50(Suppl. 1), 111–115.

Koukourakis, M. I., Touloupidis, S., Manavis, J., et al.: Conformal hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC) for high risk prostatic carcinoma: rationale, technique and early experience. Anticancer Res., 2004, 24(5B), 3239–3243.

Oliai, C., Lanciano, R., Sprandio, B., et al.: Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. J. Radiat. Oncol., 2013, 2(1), 63–70

Katz, A. J., Santoro, M., Diblasio, F., et al.: Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat. Oncol., 2013, 8(1), 118. [Epub ahead of print]